Angiodynamic Expects FY2024 Sales Of $270M-$275M, Reflects PICC And Midline Businesses Divestiture And Discontinuance Of RadioFrequency Ablation And Syntrax Businesses, Which Accounted For ~$50M Of Prior Guidance Of $320M-$325M Vs. Consensus Of $312.14M
Benzinga Newsdesk - Apr 4, 2024, 7:06AM